Posted by Michael Wonder on 03 Jun 2021
Health Canada accepts new drug submission for Reduvo as a treatment for patients with chemotherapy-induced nausea and vomiting
2 June 2021 - Tetra Bio-Pharma announced today that Health Canada has accepted its new drug submission for Reduvo and has formally entered the final review phase in the drug review process.
The active pharmaceutical ingredient in Reduvo is dronabinol, also known as THC, a synthetic form of the active natural substance in cannabis.
